Clinical Trials
23 trialsPerioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
AstraZeneca
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
M.D. Anderson Cancer Center
A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
M.D. Anderson Cancer Center
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer
University of Washington
COXEN
SWOG Cancer Research Network
Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium
Eastern Cooperative Oncology Group
Combination Chemotherapy in Treating Patients With Bladder Cancer
Eastern Cooperative Oncology Group
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
M.D. Anderson Cancer Center
4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer
SWOG Cancer Research Network
Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
Dana-Farber Cancer Institute
Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium
European Organisation for Research and Treatment of Cancer - EORTC
Combination Chemotherapy in Treating Patients With Bladder Cancer
Alliance for Clinical Trials in Oncology
Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer
M.D. Anderson Cancer Center
Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer
Hellenic Oncology Research Group
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer
University of Southern California
Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer
Memorial Sloan Kettering Cancer Center
Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer
Memorial Sloan Kettering Cancer Center
Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer
Memorial Sloan Kettering Cancer Center
Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer
Memorial Sloan Kettering Cancer Center
Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer
National Cancer Institute (NCI)
Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium
M.D. Anderson Cancer Center
Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC